Headquarters


Grünenthal Group
Zieglerstraße 6
52078 Aachen
Germany

Phone: +49 241 569-0
(24h availability for medical emergencies)

Contact Form

Adverse Drug Reaction Reporting

 

 

Global Financial Services

Requests concerning your invoices

- 00800 478 363 68 for local language

- 00800 478 363 69 for English

 

Innovating at Scale: Gabriel Baertschi Interview Economist Intelligence Unit


In an interview with the Economist Intelligence Unit our CEO talks about Grünenthal’s ambition, explains why it is necessary to go for a network based approach in R&D and what his concept of leadership is all about.

Grünenthal Clinical Trial Portal

Grünenthal Group

The Grünenthal Group

The Grünenthal Group is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation.

Our ambition is to deliver four to five new products to patients in diseases with high unmet medical need by 2022 and become a €2 billion company. We are a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients. By sustainably investing in our R&D above the industrial average, we are strongly committed to innovation.

Read more...

Commercial partnership in China

Grünenthal and Mundipharma enter into a License and Distribution Agreement.

Aachen and Beijing, January 15, 2018 – Grünenthal and Mundipharma announced today that they have entered into a License and Distribution Agreement. Under its terms, Mundipharma will market and distribute Grünenthal’s Tramal® (tramadol) in China from May 1, 2018. Developed by Grünenthal,Tramal® is a well-established analgesic for the treatment of moderate to severe pain. It is the only international brand of tramadol in China that includes sustained release tablets and immediate release capsules, as well as an intravenous formulation used for post-operative pain in patient controlled intravenous analgesia (PCIA).

Read more...